Curis, Inc. (NASDAQ:CRIS) will be discussing 3Q20 financial results with the investment community.on 10th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.curis.com
Earnings Expectation
Curis, Inc. is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.13 per share from revenue of $ 2.57 million. Looking ahead, the full year loss are expected at $ 0.66 per share on the revenues of $ 10.34 million.
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F.
